Recent advances in tumor-targeting anticancer drug conjugates

Area of Science:

• Oncology
• Pharmacology
• Drug Delivery

Background:

• Traditional chemotherapy lacks specificity, causing severe systemic toxicity and side effects.
• Tumor cells overexpress unique receptors and biomarkers, offering potential targets for selective drug delivery.
• Drug delivery systems are crucial for enhancing therapeutic efficacy and minimizing off-target effects in cancer treatment.

Purpose of the Study:

• To review recent advancements in tumor-targeting drug conjugates for improved cancer therapy.
• To discuss various tumor recognition moieties used in developing targeted drug delivery systems.
• To highlight the design principles of tumor-targeting conjugates as prodrugs with enhanced stability and targeted release.

Main Methods:

• Literature review of recent advances in tumor-targeting drug conjugates.
• Classification of conjugates based on tumor recognition moieties.
• Analysis of linker stability and cleavage mechanisms for targeted drug release.

Main Results:

• Tumor-targeting drug conjugates offer a strategy to improve drug specificity and reduce systemic toxicity.
• Various moieties, including monoclonal antibodies, folic acid, and peptides, are effective in targeting tumor cells.
• Linker stability in circulation and efficient cleavage within cancer cells are critical for conjugate efficacy.

Conclusions:

• Tumor-targeting drug conjugates represent a promising approach to enhance cancer chemotherapy efficacy and patient safety.
• The selection of appropriate tumor recognition moieties and linker technologies is key to successful conjugate design.
• Further research into novel targeting strategies and delivery systems will continue to advance cancer treatment options.